



Approved/Effective Date:

Approved by:

Annual Review by:

Date Reviewed:

## ASSESSMENT OF RISK FORM

TO BE COMPLETED FOR ANY DRUG BEING CONSIDERED FOR CONTAINMENT STRATEGIES THAT DIFFER FROM FULL NIOSH RECOMMENDATIONS, AS DEFINED IN USP GENERAL CHAPTER <800> HAZARDOUS DRUGS-HANDLING IN HEALTHCARE SETTINGS.

<b>Drug Name</b>		
<b>Dosage Form</b>	<input type="checkbox"/> Tablet / Capsule <input type="checkbox"/> Oral Liquid (commercial) <input type="checkbox"/> Compounded liquid	<input type="checkbox"/> Pre-filled syringe <input type="checkbox"/> Solution/powder for injection <input type="checkbox"/> Other:
<b>NIOSH Category:</b>	<input type="checkbox"/> Table 1: Antineoplastic Drugs that only require packaging or counting <input type="checkbox"/> Table 2: Non-antineoplastic Drugs <input type="checkbox"/> Table 3: Reproductive Toxin Drugs	
<b>Description of Packaging</b>	<input type="checkbox"/> Final dosage form, ready for dispensing directly to patient ( <i>i.e., unit dose, unit-of-use</i> ) <input type="checkbox"/> Bottle of [tablet/capsule/liquid] to be repackaged <input type="checkbox"/> Other:	
<b>Description of Required Manipulation</b>	<input type="checkbox"/> None (product available in ready-to-dispense package) <input type="checkbox"/> Repackaging only (e.g. counting; transfer container) <input type="checkbox"/> Other:	
<b>Risk of Exposure</b>	<input type="checkbox"/> Skin contact <input type="checkbox"/> Ingestion <input type="checkbox"/> Inhalation <input type="checkbox"/> Injection <input type="checkbox"/> Other (specify):	
<b>Alternative Containment Strategies and/or Work Practice</b>	<b>[Engineering Control]</b> ( <i>i.e., BSC, containment isolators, CSTDs, temporary designated prep. area</i> )]	
	<b>[Administrative Control]</b> ( <i>i.e., educational materials, acknowledgement form, training</i> )]	
	<b>[PPE Strategies]</b> ( <i>i.e., gloves, gowns, booties, head cover, face shield, eye protection, respirators</i> )]	
<b>Recommendation</b>	<input type="checkbox"/> Follow all containment requirements (as per USP<800>) <input type="checkbox"/> Follow alternative containment strategies documented above	
<small>AoR = assessment of risk; API = active pharmaceutical ingredient; CSTD = closed system drug-transfer device; HD = hazardous drug; MSHG = Manufacturer Suggested Safe Handling Guideline; NIOSH = National Institute for Occupational Safety and Health; PPE = personal protective equipment; USP = U.S. Pharmacopeia</small>		

**Important note:** The information and materials provided on these documents are intended solely for healthcare professionals seeking guidance on factors to consider in assessing risks associated with drug therapies and treatments. Any individual accessing this information should seek the counsel of their facility or employer prior to use or implementation of any information in this document. The user of this information agrees to release and hold harmless HOPA and its agents from any liability arising from use of this information.

References: [1] UC Irvine Assessment of Risk draft [2] Kienle PC, Douglass K. Perform an Assessment of Risk to Comply with USP <800>. Pharmacy Purchasing and Products. Mar 2017; 14 (3): 34. Available online at <https://www.pppmag.com/article/2012> [3] Kienle PC. The Chapter <800> Answer Book. ASHP 2017.